Mike Clayman, MD

Chief Executive Officer & Co-Founder

team-mgmt-clayman

Dr. Clayman is a co-founder and has served as our President, Chief Executive Officer, and as one of our directors since our inception in 2007. He also serves on the Board of Directors of Akebia Therapeutics. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, a global pharmaceutical company, where he was most recently Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly’s early-phase development accelerator. During his career at Lilly, Dr. Clayman also led its Global Regulatory Affairs division, the Cardiovascular Discovery Research and Clinical Investigation, Research and Development at Advanced Cardiovascular Systems, a medical device subsidiary of Lilly, the Internal Medicine Division, the Lilly Clinic, Lilly’s dedicated Phase 1 unit, and served as Chair of Lilly’s Bioethics Committee. Prior to his tenure at Lilly, Dr. Clayman was an Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease. Dr. Clayman is the recipient of the Physician Scientist Award from the National Institutes of Health. Dr. Clayman earned a B.A., cum laude, from Yale University and an M.D. from the University of California, San Diego School of Medicine. Following an internship and residency in Internal Medicine at the University of California, San Francisco Moffitt Hospitals, Dr. Clayman completed clinical and research fellowships in Nephrology at the University of Pennsylvania.

Neil Bodick, MD PhD

Chief Medical Officer & Co-Founder

Team-Photo-NeilDr. Bodick is a co-founder and has served as our Chief Medical Officer since our inception in 2007. Previously, Dr. Bodick was at Eli Lilly and Company, where he founded Chorus and served as Chief Medical Officer and Chief Operating Officer. Prior to that, Dr. Bodick was responsible for early-phase clinical investigation at Lilly Research Laboratories. Dr. Bodick also was Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the development of computer-based systems to support image-intensive diagnosis. Dr. Bodick holds 13 patents in the areas of neuroscience and computer science and is the recipient of the Biomedical Research Service Award and the New Investigator Research Award from the National Institutes of Health. Dr. Bodick earned an A.B. from Cornell University, a Ph.D. in neuroscience from Columbia University, an M.D. from the Albert Einstein College of Medicine and an M.B.A. from the Wharton School of the University of Pennsylvania.

Frederick Driscoll

Chief Financial Officer

Team-Photo-Frederick Mr. Driscoll has served as our Chief Financial Officer since May 2013. Prior to joining us, Mr. Driscoll was Chief Financial Officer at Novavax, Inc., a publicly traded biopharmaceutical company since 2009. Previously, Mr. Driscoll also served as Chief Financial Officer from 2007 to 2008, and subsequently Chief Executive Officer from 2008 to 2009, at Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company, Chief Financial Officer at Astraris, Inc., a private biotechnology company, from 2006 to 2007, and Chief Executive Officer at OXiGENE, Inc., a biopharmaceutical company, from 2002 to 2006. Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University.

Lisa Davidson, MBA

Vice President, Finance and Administration

team-mgmt-davidsonMs. Davidson has more than 20 years of broad corporate finance experience encompassing treasury management, strategic planning, operations finance, and controllership. Most recently, she served as Director of Finance at OmniSonics Medical Technologies, Inc.. Prior to that, she served in various finance, strategy and administration positions at Fisher Scientific International, Inc., Pepsi Bottling Group, and PerkinElmer Inc. Ms. Davidson has been involved in a number of M&A transactions, venture debt and equity financing totaling $90 million, and numerous product launches. She holds a BA and an MBA, both from the University of New Hampshire.

Anjali Kumar, PhD, FAHA

Vice President of Nonclinical R&D and Scientific Affairs

team-mgmt-kumarDr. Kumar brings to Flexion, nearly 15 years of experience in drug discovery, pharmacology and preclinical development gained in large pharmaceutical companies, small biotech and a consulting company environment. She has experience advancing several small molecules and proteins into initial clinical development and continuing to support them through later stages of development and eventual regulatory approval. Dr. Kumar has worked in the area of inflammation in musculoskeletal, respiratory and cardiovascular diseases. She was previously Vice President of R&D at Clinquest, Inc. where she led the strategic drug development consulting team that worked on multiple programs in both the US and in Europe. Prior to that, she was Senior Director, Pharmacology at Critical Therapeutics, Inc. and Principal Scientist and Project Leader at Wyeth Research/Genetics Institute. She received her postdoctoral training at Pharmacia and Upjohn and holds a PhD in Bioengineering from Georgia Institute of Technology and a Bachelor’s in Chemical Engineering from the Indian Institute of Technology.

Christina Willwerth, BS

Vice President of Clinical Operations and Program Management

team-mgmt-willwerthMs. Willwerth has more than 20 years of experience in pharmaceutical development. She joined Flexion from Viacell, where she was a member of the company’s Executive Management team and served as Vice President, Product Development, with management responsibility for the company’s interdisciplinary cellular therapy and fertility preservation development programs. Ms. Willwerth previously served as Senior Director, Product Development at The Medicines Company, where she focused on cardiovascular therapy clinical and product development. Prior to that, she held a number of ascendant clinical operations positions at Astra Pharmaceuticals and Biopure Corporation. Ms. Willwerth holds a BS in Biology, with high distinction, from Worcester Polytechnic Institute.